NZMP Probiotics Partnership with Sun Genomics

Sun Genomics makes probiotics branded Floré. By having individuals test their gut microflora, Floré can customise a 'precision probiotic' supplement, formulated to address indivdual needs. 

A credible supplier in the U.S. with three decades of experiencing researching these types of probiotics. NZMP was a natural choice to supply Sun Genomics with both of their clinically proven LactoB HN001™ & BifidoB HN019™ strains necessary to create this personalised probiotic for consumers. Fonterra discovered and commercialised these strains over 20 years ago and Sun Genomics has been using both HN001™ & HN019™ strains for several years.

After careful assessment of market opportunities, both parties recently recognised the benefit of working together to better understand how these super strains could target specific consumer health issues, especially with the increased concerns around immunity due to Covid-19.

Please scroll to continue reading...

NZMP and Sun Genomics journey

The relationship began in 2018 while NZMP was at Indie Bio, one of the world's largest biotech accelerators in San Francisco, recognising Sun Genomics as a high potential start-up player in the health & wellness space.

NZMP was impressed by their unique and customisable approach to consumers' health via a personalised supplement. This kind of customised product allows them to deliver a strong supplementation program and maximise the delivery of health benefits. Additionally, the two companies found Sun Genomics' work to validate their products through consumer lifestyle studies and NZMP's approach to ingredient testing through human clinical studies to be complementary.

The successful relationship between the two companies has led to more in-depth consumer research to make each companies' products even more valuable to business customers and end consumers.

Chris also explains"Working with Sun Genomics to tap into their consumer base is an innovative way to directly validate our probiotics effectiveness, and build a deeper understanding of what consumers truly need.

This novel approach to substantiating our strains is the perfect complement to our clinical research. These consumer studies will bridge the gap between meticulously designed scientific studies and the day-to-day realities of consumer life, allowing us to marry the strengths of consumer and clinical research when positioning our probiotics in the market.

This work also opens up opportunities to explore potential new formulations together, which reflects our broader efforts in addressing health benefits across physical, mental and inside-out wellness. Our focus on probiotics reflects the expansion of our classic health & wellness portfolio through our specialty ingredients."

The consumer studies include testing HN001™/HN019™ strains with Floré customers through a Fonterra-sponsored consumer project to determine if there are any significant improvements in health and mental wellness.

The results gathered in this consumer testing will provide complementary evidence to existing clinical trials on HN001™ and HN019™, by providing evidence that NZMP probiotics' benefits can also be seen outside of clinical settings and can withstand being subjected to the rigors of normal consumer lifestyles.

"We chose to work with NZMP not only because of the quality of their probiotic strains, but also because of their ability to provide clinical data and their excitement to partner and explore new spaces with us," says Neal Gidvani, the COO of Sun Genomics. "We are expecting results from some of our initial studies later this year and look forward to sharing the results with the NZMP team."

For more information about Sun Genomics, visit www.flore.com or follow on Twitter: @SunGenomics.

_{Disclaimer: This was orginally published on the PR Newswire}